Nuvation Bio Inc. Market Risk Benefit, Change in Fair Value, Gain (Loss)
Nuvation Bio Inc. (NUVB) reported Market Risk Benefit, Change in Fair Value, Gain (Loss) of $800.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Other Income
us-gaap:MarketRiskBenefitChangeInFairValueGainLoss · last filed 2026-05-04
- Nuvation Bio Inc. market risk benefit, change in fair value, gain (loss) for the quarter ending 2025-12-31 was $500.00K, a 37.50% decline year-over-year.
- Nuvation Bio Inc. market risk benefit, change in fair value, gain (loss) for the quarter ending 2025-09-30 was $600.00K, a 20.00% increase year-over-year.
- Nuvation Bio Inc. market risk benefit, change in fair value, gain (loss) for the quarter ending 2025-06-30 was $500.00K, a 54.55% decline year-over-year.
- Nuvation Bio Inc. market risk benefit, change in fair value, gain (loss) for the quarter ending 2025-03-31 was -$800.00K.
- Nuvation Bio Inc. market risk benefit, change in fair value, gain (loss) for fiscal 2025 was $800.00K, a 11.11% decline from fiscal 2024.
- Nuvation Bio Inc. market risk benefit, change in fair value, gain (loss) for fiscal 2024 was $900.00K, a 80.00% increase from fiscal 2023.
- Nuvation Bio Inc. market risk benefit, change in fair value, gain (loss) for fiscal 2023 was $500.00K, a 95.10% decline from fiscal 2022.
- Nuvation Bio Inc. market risk benefit, change in fair value, gain (loss) for fiscal 2022 was $10.20M, a 142.86% increase from fiscal 2021.
| Period end | Market Risk Benefit, Change in Fair Value, Gain (Loss) 3 month | Market Risk Benefit, Change in Fair Value, Gain (Loss) 6 month | Market Risk Benefit, Change in Fair Value, Gain (Loss) 9 month | Market Risk Benefit, Change in Fair Value, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.10M derived: sum of 2 quarters · filed 2026-03-02 | $1.60M derived: sum of 3 quarters · filed 2026-03-02 | $800.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $1.10M derived: sum of 2 quarters · filed 2025-11-03 | $300.00K 10-Q · filed 2025-11-03 | $1.10M derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$300.00K 10-Q · filed 2025-08-07 | $500.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-03-31 | -$800.00K 10-Q · filed 2026-05-04 | $0.00 derived: sum of 2 quarters · filed 2026-05-04 | $500.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.60M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $800.00K derived: 10-K 12 month − 3 quarters · filed 2025-03-06 | $1.30M derived: sum of 2 quarters · filed 2025-03-06 | $2.40M derived: sum of 3 quarters · filed 2025-03-06 | $900.00K 10-K · filed 2025-03-06 |
| 2024-09-30 | $500.00K 10-Q · filed 2024-11-06 | $1.60M derived: sum of 2 quarters · filed 2024-11-06 | $100.00K derived: sum of 3 quarters · filed 2024-11-06 | $300.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | $1.10M 10-Q · filed 2024-08-05 | -$400.00K derived: sum of 2 quarters · filed 2024-08-05 | -$200.00K derived: sum of 3 quarters · filed 2024-08-05 | $200.00K derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | -$1.50M 10-Q · filed 2024-05-14 | -$1.30M derived: sum of 2 quarters · filed 2024-05-14 | -$900.00K derived: sum of 3 quarters · filed 2024-05-14 | -$600.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $600.00K derived: sum of 2 quarters · filed 2024-02-29 | $900.00K derived: sum of 3 quarters · filed 2024-02-29 | $500.00K 10-K · filed 2024-02-29 |
| 2023-09-30 | $400.00K 10-Q · filed 2023-11-02 | $700.00K derived: sum of 2 quarters · filed 2023-11-02 | $300.00K 10-Q · filed 2023-11-02 | $1.10M derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | $300.00K 10-Q · filed 2023-08-03 | $100.00K 10-Q · filed 2023-08-03 | $700.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.20M derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-04 | $400.00K derived: sum of 2 quarters · filed 2023-05-04 | $900.00K derived: sum of 3 quarters · filed 2023-05-04 | $4.00M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $800.00K derived: sum of 2 quarters · filed 2023-03-15 | $3.90M derived: sum of 3 quarters · filed 2023-03-15 | $10.20M 10-K · filed 2023-03-15 |
| 2022-09-30 | $500.00K 10-Q · filed 2022-11-03 | $3.60M derived: sum of 2 quarters · filed 2022-11-03 | $9.90M 10-Q · filed 2022-11-03 | $13.80M derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | $3.10M 10-Q · filed 2022-08-04 | $9.40M 10-Q · filed 2022-08-04 | $13.30M derived: sum of 3 quarters · filed 2022-08-04 | $13.40M derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | $6.30M 10-Q · filed 2022-05-09 | $10.20M derived: sum of 2 quarters · filed 2022-05-09 | $10.30M derived: sum of 3 quarters · filed 2022-05-09 | $10.80M derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.00M derived: sum of 2 quarters · filed 2022-02-28 | $4.50M derived: sum of 3 quarters · filed 2022-02-28 | $4.20M 10-K · filed 2022-02-28 |
| 2021-09-30 | $100.00K 10-Q · filed 2021-11-10 | $600.00K derived: sum of 2 quarters · filed 2021-11-10 | $300.00K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $500.00K 10-Q · filed 2021-08-12 | $200.00K 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $300.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |